A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer.

[1]  Chunxu Qu,et al.  Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia. , 2021, Blood.

[2]  S. Fosmire,et al.  A Regulatory Loop of FBXW7-MYC-PLK1 Controls Tumorigenesis of MYC-Driven Medulloblastoma , 2021, Cancers.

[3]  J. Dick,et al.  CC-90009, a novel cereblon E3 ligase modulator targets acute myeloid leukemia blasts and leukemia stem cells. , 2020, Blood.

[4]  B. Kuster,et al.  PROTAC-mediated degradation reveals a non-catalytic function of AURORA-A kinase , 2020, Nature Chemical Biology.

[5]  N. Gray,et al.  Selective Degradation of GSPT1 by Cereblon Modulators Identified via a Focused Combinatorial Library. , 2020, ACS chemical biology.

[6]  Richard J. Jones,et al.  The novel protein homeostatic modulator BTX306 is active in myeloma and overcomes bortezomib and lenalidomide resistance , 2020, Journal of Molecular Medicine.

[7]  W. Xue,et al.  A Cereblon Modulator CC-885 Induces CRBN- and p97-Dependent PLK1 Degradation and Synergizes with Volasertib to Suppress Lung Cancer , 2020, Molecular therapy oncolytics.

[8]  Hans-Peter Lenhof,et al.  GeneTrail 3: advanced high-throughput enrichment analysis , 2020, Nucleic Acids Res..

[9]  Bin Liu,et al.  The novel cereblon modulator CC-885 inhibits mitophagy via selective degradation of BNIP3L , 2020, Acta Pharmacologica Sinica.

[10]  M. Eilers,et al.  Targeting MYC Proteins for Tumor Therapy , 2020, Annual Review of Cancer Biology.

[11]  R. Deshaies,et al.  Harnessing the Power of Proteolysis for Targeted Protein Inactivation. , 2020, Molecular cell.

[12]  C. Crews,et al.  Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery , 2020, Cell.

[13]  Zhaomin Liu,et al.  Simple Structural Modifications Converting a Bona Fide MDM2 PROTAC Degrader into a Molecular Glue Molecule: A Cautionary Tale in the Design of PROTAC Degraders. , 2019, Journal of medicinal chemistry.

[14]  Matthieu Schapira,et al.  Targeted protein degradation: expanding the toolbox , 2019, Nature Reviews Drug Discovery.

[15]  Philip P. Chamberlain,et al.  Development of targeted protein degradation therapeutics , 2019, Nature Chemical Biology.

[16]  R. Sears,et al.  Mission Possible: Advances in MYC Therapeutic Targeting in Cancer , 2019, BioDrugs.

[17]  C. Hellen.  Translation Termination and Ribosome Recycling in Eukaryotes. , 2018, Cold Spring Harbor perspectives in biology.

[18]  C. Crews,et al.  Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance , 2018, Communications Biology.

[19]  S. Holstein,et al.  Next-Generation Drugs Targeting the Cereblon Ubiquitin Ligase. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Andrea Sottoriva,et al.  Patient-derived organoids model treatment response of metastatic gastrointestinal cancers , 2018, Science.

[21]  K. Bennett,et al.  Translation Termination Factor GSPT1 Is a Phenotypically Relevant Off-Target of Heterobifunctional Phthalimide Degraders. , 2018, ACS chemical biology.

[22]  S. Tirrell,et al.  A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment , 2018, Nature Medicine.

[23]  C. Crews,et al.  Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead. , 2017, Cell chemical biology.

[24]  Ann E. Sizemore,et al.  Computational correction of copy-number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells , 2017, Nature Genetics.

[25]  D. Lamont,et al.  Structural basis of PROTAC cooperative recognition for selective protein degradation , 2017, Nature chemical biology.

[26]  G. Qing,et al.  Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival. , 2016, Molecular cell.

[27]  G. Schneider,et al.  Concepts to Target MYC in Pancreatic Cancer , 2016, Molecular Cancer Therapeutics.

[28]  Chin-Chun Lu,et al.  A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase , 2016, Nature.

[29]  C. Crews,et al.  PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer , 2016, Proceedings of the National Academy of Sciences.

[30]  J. Mesirov,et al.  The Molecular Signatures Database Hallmark Gene Set Collection , 2015 .

[31]  I. E. Smith,et al.  HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins. , 2015, ACS chemical biology.

[32]  Dennis L. Buckley,et al.  Selective Target Protein Degradation via Phthalimide Conjugation , 2015 .

[33]  S. Carr,et al.  Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS , 2015, Nature.

[34]  Christopher J. Ott,et al.  The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins , 2014, Science.

[35]  S. Carr,et al.  Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells , 2014, Science.

[36]  Qiang Yu,et al.  PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy. , 2013, Cancer discovery.

[37]  Toshihiko Ogura,et al.  Identification of a Primary Target of Thalidomide Teratogenicity , 2010, Science.

[38]  John S Lazo,et al.  Low molecular weight inhibitors of Myc–Max interaction and function , 2003, Oncogene.

[39]  Jacob D. Jaffe,et al.  Next-generation characterization of the Cancer Cell Line Encyclopedia , 2019, Nature.